Rich HCC clinical pipeline can lead to $3.8 billion sales by 2027 for G8

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, and, also a leading cause of cancer-related deaths worldwide.

The incidence and subsequent mortality of the disease is on a continuous upsurge despite gradually improving screening, diagnosis, and treatment. The disease is found to be more common in males as compared to females, according to a new report, " Hepatocellular Carcinoma (HCC) Market Insights, Epidemiology and Market Forecast-2027" added to the offering of DelveInsight.

According to the DelveInsight report, the total incident cases of HCC in the G8 countries, ie, the USA, EU5 (Germany, France, Italy, Spain and the UK), Japan and China, were found to be 458, 170 in 2016, while the corresponding diagnosed advanced HCC cases in the G8 countries were found to be 160,565 for the same year.